-2%
- Central (cranial) diabetes insipidus
- Temporary polyuria and polydipsia following head trauma or pituitary surgery
- Primary nocturnal enuresis
- Nocturia due to nocturnal polyuria
- Hemophilia A
- Von Willebrand Disease (Type 1)
- Uremic bleeding in acute or chronic renal failure
Enurex Solution contains desmopressin, a synthetic analogue of the natural antidiuretic hormone vasopressin, which plays a key role in regulating the body’s water balance. It works by increasing water reabsorption in the kidneys, thereby reducing excessive urine output and controlling abnormal thirst in patients with diabetes insipidus.
Enurex Solution is also effective in decreasing night-time urine production, making it useful in the management of nocturnal enuresis (bedwetting) and nocturia. Additionally, it has haemostatic properties, as it stimulates the release of clotting factors, helping to reduce bleeding episodes in conditions such as Hemophilia A, Von Willebrand Disease (Type 1), and uremic bleeding associated with acute or chronic renal failure.
Adult Dosage
Diabetes Insipidus
Intranasal:
10–40 mcg once daily, administered as a single dose or divided into 2–3 doses
Usual dose: 20 mcg daily in 2 divided doses
Morning and evening doses should be adjusted to maintain normal daily water balance
Oral:
Initial: 0.05 mg every 12 hours
Effective range: 0.1–1.2 mg/day in divided doses every 8–12 hours
Fluid intake restriction is essential
IV/SC:
2–4 mcg/day in divided doses every 12 hours
Approximately one-tenth of the intranasal maintenance dose
Hemophilia A
IV:
0.3 mcg/kg administered over 15–30 minutes
For surgical procedures, give 30 minutes prior
Intranasal:
<50 kg: 150 mcg
≥50 kg: 300 mcg
For preoperative use, administer 2 hours before the procedure
Von Willebrand Disease (Type 1)
IV:
0.3 mcg/kg over 15–30 minutes
Preoperative dose: 30 minutes before surgery
Intranasal:
<50 kg: 150 mcg
≥50 kg: 300 mcg
Administer 2 hours prior to procedure
Nocturnal Enuresis
Oral: 0.2 mg at bedtime
May be increased up to 0.6 mg/day if required
Nocturia (Adults)
Preservative-free nasal spray:
Ages 50–<65 years: 1.66 mcg nightly, 30 minutes before bedtime
≥65 years: 0.83 mcg nightly; dose may be increased after 7 days if serum sodium remains normal
Sublingual tablets:
Women: 27.7 mcg once daily, 1 hour before bedtime
Men: 55.3 mcg once daily, 1 hour before bedtime
Administer without water and only if serum sodium is normal
Uremic Bleeding
0.4 mcg/kg IV over 10 minutes
Pediatric Dosage
Diabetes Insipidus
3 months–12 years: 5–30 mcg intranasally once daily, as a single dose or divided
>12 years: 10–40 mcg once daily in divided doses
Dosage should be individualized to maintain appropriate diurnal water balance
Nocturnal Enuresis
Children >6 years: 0.2 mg orally at bedtime (maximum 0.6 mg/day)
Hemophilia A & Von Willebrand Disease
IV:
0.3 mcg/kg administered 30 minutes before procedures
Intranasal:
<50 kg: 150 mcg
≥50 kg: 300 mcg
Fluid intake should be restricted from 1 hour before dosing until at least 8 hours after
Renal Dose Adjustment
CrCl <50 mL/min: Contraindicated
CrCl ≥50 mL/min: No dose adjustment required
May be used off-label in uremic bleeding under specialist supervision
